of prognosis in patients w

role in the pathophysiology of chronic heart failure. Plasma levels of immunoreactive adrenomedullin were examined for prediction of prognosis in chronic heart failure. Methods and Results Plasma levels of immunoreactive-ADM (ir-ADM) were measured by radioimmunoassay in 117 chronic heart failure patients with idiopathic or ischae-diastolic diameter, plasma levels of immunoreactive adrenomedullin, endothelin-1, norepinephrine and atrial natriuretic peptide was performed: plasma levels of immunoreactive adrenomedullin (P=0·03), of endothelin-1 (P=0·0001), and systolic blood pressure (P=0·003) were significantly associated with outcome. Conclusion Our results suggest that elevated plasma levels Human adrenomedullin, discovered in 1993, is a 52- an atrial natriuretic peptide in the control of cardiorenal amino-acid peptide with a structural homology relate